The purpose of this study is to document the clinical benefit of quetiapine (Seroquel) sustained release (SR) after switching from another ongoing antipsychotic treatment, regardless of the reason for the switch. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
550
Research Site
Vancouver, British Columbia, Canada
Research Site
Aurora, Ontario, Canada
The proportion of patients who have an improved clinical benefit based on assessment of clinical efficacy in combination with assessment of tolerability
The change from baseline in Clinical Global Impression (CGI)-CB score
Change from baseline in Positive and Negative Syndrome Scale (PANSS) total score
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Burlington, Ontario, Canada
Research Site
Mississauga, Ontario, Canada
Research Site
Orléans, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Québec, Quebec, Canada
Research Site
Saint-Laurent, Quebec, Canada
Research Site
Sherbrooke, Quebec, Canada
Research Site
Prince Albert, Saskatchewan, Canada
...and 17 more locations